Credit: CristianCamiloAcevedoOrozco, https://commons.wikimedia.org/wiki/File:Pluma_inyectable_de_liraglutida.jpg, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons
Credit: CristianCamiloAcevedoOrozco, https://commons.wikimedia.org/wiki/File:Pluma_inyectable_de_liraglutida.jpg, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons

How those diabetes and weight loss drugs may be helping hearts

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.

People: This is a study based on research using people.

People with diabetes who received a drug in the same group of diabetes/weight loss drugs as Ozempic - a glucagon-like peptide-1 receptor agonist (GLP-1 RA) called liraglutide -  improved key markers of heart health, according to international and Australian research. The researchers found that, compared to another type of diabetes drug, those taking liraglutide for 16 weeks improved key measures of heart health. These measures are thought to point to potential ways that heart disease develops in type 2 diabetes. The researchers say the effects of liraglutide on these measures offer important insights into how these drugs might be having beneficial effects on heart disease as well as diabetes.

Journal/conference: Journal of the American College of Cardiology

Research: Paper

Organisation/s: Baker Heart and Diabetes Institute, Monash University, The University of Melbourne, University of Leeds, UK

Funder: This independent research has been jointly funded by the Wellcome Trust (grant number: 221690/Z/20/Z) and Diabetes UK (grant number:18/0005870) and has been performed at the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC) (NIHR203331). Funding for open access charge is from Wellcome Trust (grant number: 221690/Z/20/Z). Dr Chowdhary has received grants from the British Heart Foundation (grant number: FS/CRTF/20/24003). Dr Valkovic has received grants from the Sir Henry Dale Fellowship supported jointly by the Wellcome Trust and the Royal Society (#221805/Z/20/Z), and Slovak Grant Agencies VEGA (#2/0004/23) and APVV (#21-0299). Dr Levelt acknowledges support from the Wellcome Trust Clinical Career Development Fellowship (grant number: 221690/Z/20/Z), Diabetes UK (grant number: UK 18/0005908) and the NIHR Leeds Biomedical Research Centre.

Attachments:

Note: Not all attachments are visible to the general public

  •  Research
    American College of Cardiology
    Web page
    Please link to the article in online versions of your report (the URL will go live after the embargo ends).
  •  Editorial / Opinion
    American College of Cardiology
    Web page
    Please link to the article in online versions of your report (the URL will go live after the embargo ends).

News for:

Australia
International
VIC

Media contact details for this story are only visible to registered journalists.